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ABSTRACT
Stevens-Johnson syndrome (SJS) is a rare, serious disorder affecting skin and mucous membranes. It is one of the few serious dermatological adverse 
effects of drugs encountered in clinical practice which is characterized by blisters and rash on skin, mucous membranes, swelling over face and 
lips, and hyperpigmentation. After that, the outer layer of affected skin becomes dead, sheds, and starts to heal after several days of inflicting injury. 
Here, we present a case series of ofloxacin and chloroquine induced SJS after the consent given by patients. First case is a 62 years old male received 
Ofloxacin and second patient is a 40 years old male received chloroquine. Both patients experienced a severe skin reaction which was diagnosed as 
SJS. The above-mentioned medications will be implicated in cases of SJS. We should prescribe these medications with extreme caution.
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INTRODUCTION
Stevens-Johnson syndrome (SJS) is a serious unfavorable mucocutaneous 
drug reaction mainly affecting the skin and mucous membranes. This is 
basically an immune-mediated hypersensitivity reaction [1] and most 
commonly associated with drug exposure [2]. Ofloxacin is one of the most 
commonly used fluoroquinolone because of easy accessibility, availability 
and cost-benefit ratio. Chloroquine is also a commonly prescribed drug 
for malaria, rheumatoid arthritis, and amoebic liver abscess. Both the 
drugs are considered as comparatively safer, but undesirable, untoward 
adverse effects mainly cutaneous hypersensitivity reactions have been 
reported in only few instances due to these drugs [3,4].
Consent from patients




A 62-year-old male patient presented in dermatology outpatients 
department with complaints of rapidly progressive rashes which 
became hyperpigmented on all over his body. Patient gave a positive 
history of abdominal pain with associated diarrhea for which he took 
ofloxacin tablets. On the next day, he developed acute generalized 
erythematous rashes with itching all over his body including face, 
upper and lower extremities, scalp, and trunk. He also developed 
erosive lesions over oral mucosa and mild congestion in his conjunctiva 
(Figs. 1 and 2). 
On the examination, patient was conscious, well oriented to time, 
place and person and stable with mild febrile condition (38.5°C) and 
hypotensive (102/72 mm Hg). Pulse rate was 76 bpm and respiratory 
rate was 21/min. Blister formation on some parts of body was also 
present. Erosion and crusting over lip was also noticed. There was no 
hepatosplenomegaly or lymphadenopathy.
Platelet count in this patient was normal and his total white blood 
cell (WBC) count was 4.98×109/L. His hemoglobin value was 
12.3 g/dl. Liver function tests showed mild elevation in alanine 
aminotransferase (703 U/L) and aspartate aminotransferase (92 
U/L) level. Erythrocyte sedimentation rate (ESR) was 54 mm/h. 
Serum creatinine was 1.2 mg/dl. Systemic examinations did not 
tell any significant findings. Other laboratory findings were within 
normal range.
On the basis of history, clinical examinations and findings, this patient 
was diagnosed as a case of SJS which is due to ofloxacin intake. 
Patient was admitted in the hospital and treated with antihistamines, 
intravenously (IV) administered dexamethasone (4 mg/day for 5 days) 
and 2% fusidic acid cream was applied topically. Carboxymethyl 
cellulose eye drop was also prescribed for the relief in conjunctival 
congestion and irritation. Later he was continued on tablet methyl 
prednisolone 20 mg/day. Intravenous fluid therapy, symptomatic, and 
supportive treatment had been done for optimum care of the patient. 
He showed significant improvement in his condition within 12 days. 
Then patient was discharged with oral steroid. Dose of steroid was 
tapered gradually over next 2 weeks. Almost all lesions totally resolved 
in a few weeks leaving post-inflammatory hyperpigmentation over his 
body without any other complications.
Patient 2
A 40 years old male was brought to the emergency department of the 
hospital with painful skin rashes, blisters, and erosions all over the body 
accompanied by fever and myalgia. It started on the 2nd day during the 
course of chloroquine therapy given by a local practitioner for empirical 
treatment of malaria. The rashes appeared on the trunk initially (Fig. 3) 
and then slowly progressed to involve the extremities and mouth also. 
Rashes were papular erythematous eruptions coupled with itching. 
The lesions became hyperpigmented later on. On the basis of history, 
clinical examinations and relevant findings, he was diagnosed as a case 
of SJS induced by chloroquine. He also had difficulty in swallowing due 
to painful erosions of the mouth and oropharynx. It was associated 
with bilateral conjunctivitis but there was no visual impairment. His 
hemoglobin value was 13.4 g/dl and platelets were in normal range. 
The total WBCs count was 8.1×109/L along with normal liver and renal 
function tests. Serum creatinine was 1.1 mg/dl. ESR was 25 mm/h. 
Investigations also showed the negative findings for malaria parasite 
and Widal test. Systemic examinations did not tell any relevant findings. 
Other laboratory values and findings were within the normal limits.
Patient was admitted and treated for 1 week with IV fluids, injection 
ceftriaxone 1 g, 12 hourly, IV after sensitivity testing to prevent 
secondary infections, injection hydrocortisone 100 mg, 8 hourly 
IV, tablet ranitidine 150 mg BD, tablet cetirizine 10 mg OD, local 
application of glycerine for soothing effect and fusidic acid cream (2%) 
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as antiseptic for 7 days. Finally, the patient improved and discharged 
successfully.
There was no history of any drug allergy and he had not taken 
chloroquine in the past. No other drugs were taken concomitantly. Other 
blistering skin diseases like bullous pemphigoid and pemphigus vulgaris 
were excluded from the diagnosis on the basis of clinical grounds. 
Thus, the above-mentioned SJS has a strong temporal association to 
chloroquine intake. However, rechallenge is not justified in this case 
due to ethical constraints and fatal outcomes. This adverse reaction 
is not dose related. It can be considered as Probable/Likely adverse 
drug reaction as per causality assessment of suspected adverse drug 
reactions [5]. 
DISCUSSION
The pathogenesis of SJS is not fully understood, but is believed to 
be an immune-mediated hypersensitivity reaction. The clinical, 
histopathological, and immunological findings in SJS support the 
concept that SJS is a specific drug hypersensitivity adverse reaction in 
which cytotoxic T lymphocytes play predominant role in the initiation 
phase of the reaction [6]. The estimated incidence of the SJS ranges 
between 1.2 and 6/million populations/year but the mortality rate is 
nearly 15%. HIV positive patients appear to be at an enhanced risk of 
developing the SJS. 
The use of fluoroquinolones like ofloxacin has been increasing due 
to their broad spectrum antimicrobial action, easy availability, and 
fewer side effects. Until now, these drugs have seldom been implicated 
in patients with SJS, but the incidence of fluoroquinolone-induced 
cutaneous drug reactions may be on the rise. There are very few reports 
of antimalarial drug chloroquine evoked SJS; however, it is usually 
unnoticed in its adverse result profile. 
Injudicious uses of antibiotics are the foremost common reasons behind 
SJS, followed by analgesic drugs, cold and cough medications, antipsychotic 
drugs, antiepileptics, and allopurinol within the general population. Among 
antibiotics, penicillin, and sulpha drugs are main culprit and very few cases 
of chloroquine and fluoroquinolone induced SJS are also reported [7]. 
Some of these drugs may also be adulterated because of increased access 
through the internet and no strict regulation on their sale in the market.
Thus, the idea of this written statement is to create awareness about 
the rare but potentially fatal drug reaction such as SJS with ofloxacin 
and chloroquine which is commonly used for the treatment of bacterial 
infections and malaria, respectively, in India and in other countries.
CONCLUSION 
The side effects of fluoroquinolones such as ofloxacin and chloroquine 
now be broadened to rarely include SJS and should be considered in 
patients presenting with similar clinical features and manifestations in 
the form of mucocutaneous side effects due to these offending drugs. As 
with other symptoms more commonly associated with this condition, 
these may resolve after discontinuation of the offending medication. 
Further studies are warranted to elucidate the relationship and the 
mechanism by which ofloxacin and chloroquine can cause SJS. 
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Fig. 1: Erosive lesions over oral mucosa
Fig. 2: Erythematous rashes over scalp
Fig. 3: Rashes over trunk
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